Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

Plasmodium falciparum Liver Stage Antigen 1 (LSA-1) is a pre-erythrocytic stage antigen. Our LSA-1 vaccine candidate is a recombinant protein with full-length C- and N-terminal flanking domains and two of the 17 amino acid repeats from the central repeat region termed "LSA-NRC." We describe the first Phase I/II study of this recombinant LSA-NRC protein formulated with either the AS01 or AS02 adjuvant system. We conducted an open-label Phase I/II study. Thirty-six healthy malaria-naïve adults received one of four formulations by intra-deltoid injection on a 0 and 1 month schedule; low dose (LD) LSA-NRC/AS01:10microg LSA-NRC/0.5ml AS01 (n=5), high dose (HD) LSA-NRC/AS01: 50microg LSA-NRC/0.5ml AS01 (n=13); LD LSA-NRC/AS02: 10microg LSA-NRC/0.5ml AS02 (n=5) and HD LSA-NRC/AS02: 50microg LSA-NRC/0.5ml AS02 (n=13). Two weeks post-second immunization, the high dose vaccinees and 6 non-immunized infectivity controls underwent experimental malaria sporozoite challenge. The vaccines showed a reassuring safety profile but were moderately reactogenic. There were no serious adverse events. All subjects seroconverted after the first immunization. Following the second immunization, LSA-1-specific CD4+ T cells producing two cytokines (IL-2 and IFN-gamma) were found by intra-cellular staining in all subjects in the LD LSA-NRC/AS01B group and in 3 of 5 subjects in the LD LSA-NRC/AS02 group. In contrast, the HD LSA-NRC/AS01 and HD LSA-NRC/AS02 group subjects had fewer LSA-1-specific CD4+ T cells, and minimal to no IFN-gamma responses. There was no increase in LSA-1-specific CD8+ T cells found in any group. Per protocol, 22 high dose vaccinees, but no low dose vaccinees, underwent P. falciparum homologous malaria challenge (3D7 clone). All vaccinees became parasitemic and there was no delay in their pre-patent period versus controls (p=0.95). LSA-NRC/AS01 and LSA-NRC/AS02 elicited antigen-specific antibody and CD4+ T cell responses, but elicited no protective immunity. Although the optimal antigen dose of LSA-NRC may not have been selected for the challenge portion of the protocol, further vaccine development based upon LSA-1 should not be excluded and should include alternative vaccine platforms able to elicit additional effector mechanisms such as CD8+ T cells.

[1]  S Walters,et al.  T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic , 1997, Infection and immunity.

[2]  V. Appay,et al.  Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[3]  B. Lell,et al.  Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria. , 1999, European cytokine network.

[4]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[5]  M. Alpers,et al.  Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. , 1995, Molecular and biochemical parasitology (Print).

[6]  F. Migot-Nabias,et al.  Factors influencing resistance to reinfection with Plasmodium falciparum. , 1999, The American journal of tropical medicine and hygiene.

[7]  J. Kurtis,et al.  Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. , 2001, Trends in parasitology.

[8]  L. BenMohamed,et al.  Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. , 1994, Journal of immunology.

[9]  J. Harty,et al.  CD8+ T cell contraction is controlled by early inflammation , 2004, Nature Immunology.

[10]  U. Krzych,et al.  The dissection of CD8 T cells during liver-stage infection. , 2005, Current topics in microbiology and immunology.

[11]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[12]  M. Aidoo,et al.  Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.

[13]  B. Lell,et al.  Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. , 1999, The Journal of infectious diseases.

[14]  W. Ripley Ballou,et al.  Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1 , 2003, The Journal of Immunology.

[15]  S. Hoffman,et al.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.

[16]  L. Rénia,et al.  Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. , 1993, Journal of immunology.

[17]  S. Hoffman,et al.  Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites , 2005, Infection and Immunity.

[18]  I. Schneider,et al.  T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. , 1995, Journal of immunology.

[19]  V. A. Stewart,et al.  Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates , 2007, Infection and Immunity.

[20]  Purnomo,et al.  Assessment of age-dependent immunity to malaria in transmigrants. , 1997, The American journal of tropical medicine and hygiene.

[21]  L. Rénia,et al.  In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Angov,et al.  Process Development and Analysis of Liver-Stage Antigen 1, a Preerythrocyte-Stage Protein-Based Vaccine for Plasmodium falciparum , 2005, Infection and Immunity.

[23]  J. Stephenson,et al.  Defective adenoviruses as novel vaccines for the Flaviviridae. , 1998, Clinical and diagnostic virology.

[24]  V. A. Stewart,et al.  Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.

[25]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[26]  D. Webster,et al.  Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans , 2003, Nature Medicine.

[27]  M. Demoitié,et al.  Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A , 2006, Infection and Immunity.

[28]  C. Atkinson,et al.  Non-CS pre-erythrocytic protective antigens. , 1990, Immunology letters.

[29]  J. Kurtis,et al.  Interleukin-10 Responses to Liver-Stage Antigen 1 Predict Human Resistance to Plasmodium falciparum , 1999, Infection and Immunity.

[30]  S. Hoffman,et al.  Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. , 1986, The American journal of tropical medicine and hygiene.

[31]  J. Barnwell,et al.  Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. , 2006, The American journal of tropical medicine and hygiene.

[32]  G. Trinchieri,et al.  Interleukin-10 production by effector T cells: Th1 cells show self control , 2007, The Journal of experimental medicine.

[33]  C. John,et al.  Gamma Interferon Responses to Plasmodium falciparum Liver-Stage Antigen 1 and Thrombospondin-Related Adhesive Protein and Their Relationship to Age, Transmission Intensity, and Protection against Malaria , 2004, Infection and Immunity.

[34]  M. Demoitié,et al.  Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2008, Vaccine.

[35]  G. Weverling,et al.  Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 , 2008, Infection and Immunity.